• 2021-09-08 14:0:00.0 DelSiTech and Visus Therapeutics enter into Patent Licensing Arrangement
  • 2021-09-08 14:0:00.0 Slow-Release Jab for Child Growth Hormone Deficiency Gets FDA Nod
  • 2021-09-09 9:0:00.0 US FDA accepts Teva-MedinCell’s new drug application for drug to treat schizophrenia
  • 2021-09-10 9:0:00.0 US FDA accepts Teva-MedinCell’s new drug application for drug to treat schizophrenia
  • 2021-09-13 13:0:00.0 FDA Accepts NDA for Subcutaneous Risperidone Injectable
  • 2021-09-13 13:0:00.0 Ascendis Pharma A/S Submits Investigational New Drug
  • 2021-09-14 12:54:00.0 Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform
  • 2021-09-20 16:0:00.0 Hanmi Pharmaceutical has confirmed the efficacy of LAPSGLP-2 Analog, a short bowel syndrome treatment candidate
  • 2021-09-23 11:0:00.0 LeaderMed Group and OPKO Health Form Joint Venture to develop an oxyntomodulin analog
  • 2021-09-23 16:10:00.0 FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease
  • 2021-09-23 16:10:00.0 Vutrisiran Under Review for Approval in Europe for FAP Treatment
  • 2021-09-23 16:10:00.0 MedAlliance announces completion of enrollment in Japanese SELUTION SLR™ Study
  • 2021-09-23 16:10:00.0 A 'game-changing' treatment in the opioid-dependence fight
  • 2021-10-01 16:10:00.0 HIV treatment evolution: drug development to meet the modern needs of patients
  • 2021-09-30 16:10:00.0 Rice University lands grant to improve time-release drugs
  • 2021-10-05 11:9:00.0 Daewoong wins Australian approval to conduct clinical trial of hair-loss treatment
  • 2021-10-06 16:10:00.0 Small but mighty - Article by Noor Al-Rifai CEng MIChemE and Rene Holm
  • 2021-10-05 16:10:00.0 FDA Grants Priority Review for Cabotegravir to Prevent HIV
  • 2021-10-04 16:10:00.0 PROVENT Trial's AZD7442 demonstrated statistical significance in protecting against symptomatic COVID-19 infection
  • 2021-10-11 16:10:00.0 AstraZeneca seeks FDA approval for COVID-19 antibody treatment
  • 2021-10-13 16:10:00.0 PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer
  • 2021-10-14 16:10:00.0 NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy
  • 2021-10-16 16:10:00.0 AstraZeneca gets positive results from COVID-19 drug trial
  • 2021-10-16 16:10:00.0 18-Month Below-the-Knee Data with MedAlliance's SELUTION SLR™ Presented as Late Breaking Trial at VIVA
  • 2021-10-25 16:10:00.0 Trials for clinical injectable ARVs start in Uganda
  • 2021-10-26 16:10:00.0 VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease
  • 2021-11-12 16:10:00.0 AstraZeneca files for Health Canada approval of new COVID-19 therapy
  • 2021-11-19 16:10:00.0 'Great step forward’ for HIV treatment as long-acting jabs to replace daily pills
  • 2021-11-20 16:10:00.0 Long-Acting Antibody Combo Reduced Risk of Symptomatic COVID-19 in Phase 3 Trials
  • 2021-11-21 16:10:00.0 NIH Grant Boosts Delpor’s Plans for Tizanidine Implant
  • 2021-11-26 16:10:00.0 Europe gives green light to first long-acting injectable treatment for schizophrenia in adults
  • 2021-12-03 16:10:00.0 WHO Approves First Long-Acting Device to Shield Women From HIV
  • 2021-12-03 16:10:00.0 NIH Statement on World AIDS Day 2021
  • 2021-12-10 16:10:00.0 The Medicines Patent Pool and the University of Washington sign a licence agreement for an investigational long-acting injectable HIV drug combination candidate
  • 2021-12-10 16:10:00.0 AstraZeneca’s long-acting antibody drug lands FDA authorisation for COVID-19
  • 2021-12-20 16:10:00.0 National Institute of Health and Care Excellence has signed off on offering pre-exposure prophylaxis treatment to people at a high risk of contracting HIV
  • 2022-01-14 16:10:00.0 Implementing Injectables
  • 2022-01-24 16:10:00.0 New Injectable HIV Prevention Drug Approved By FDA
  • 2022-02-06 16:10:00.0 Long-acting injectable for HIV prevention 'overpriced'
  • 2022-02-06 16:10:00.0 GlaxoSmithKline's HIV drug Cabenuva scores FDA nod for 2-month dosing
  • 2022-02-06 16:10:00.0 Injectables for schizophrenia reduce hospitalisations better than oral medications, study shows
  • 2021-09-23 16:10:00.0 MHRA approval for Byannli
  • 2022-02-06 16:10:00.0 HIV Prevention, Treatment: Playing the Long Game
  • 2022-02-14 13:0:00.0 ViiV Healthcare Long-acting HIV treatment secures FDA approval
  • 2022-02-28 9:10:00.0 Lenacapavir shows continued promise for first-line treatment and highly resistant HIV
  • 2022-02-28 16:10:00.0 Europe Accelerates Long-acting RSV Antibody Assessment in Infants
  • 2022-02-28 9:0:00.0 Pfizer gets EU approval for long-acting human growth hormone, softening blow of FDA rejection
  • 2022-02-28 16:10:00.0 Long-acting HIV-1 Capsid Inhibitor Sustained Efficacy in Phase 2/3 Study
  • 2022-03-04 16:10:00.0 Long-acting monoclonal antibody shows potential to offer RSV protection for all infants
  • 2022-04-01 16:10:00.0 Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain
  • 2022-04-01 16:10:00.0 Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevent
  • 2022-04-01 16:10:00.0 U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Re
  • 2021-09-23 9:0:00.0 Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir
  • 2022-05-23 9:0:00.0 DelSiTech and Anticancer Bioscience Announce a Collaboration Agreement for the Development of Long-acting Therapies in Oncology
  • 2022-05-23 9:0:00.0 FDA Lifts Clinical Hold on Long-Acting Lenacapavir
  • 2022-05-31 9:0:00.0 Second-Generation Long-Acting Injectables Significantly Improve Long-Term Severe Schizophrenia Outcomes
  • 2022-05-27 9:0:00.0 MedAlliance's SELUTION SLR drug-eluting balloon (DEB) receives FDA investigational device exemption (IDE) approval
  • 2022-05-31 9:0:00.0 ViiV Healthcare and MPP are actively negotiating voluntary licensing terms to help widen access to innovative HIV prevention measure
  • 2022-06-24 9:0:00.0 Investigational Lenacapavir Receives Positive CHMP Opinion for investigational lenacapavir for the treatment of HIV-1 infection
  • 2022-06-27 9:0:00.0 Gilead Sciences Resubmits NDA to FDA for Lenacapavir
  • 2022-06-01 9:0:00.0 Combination anti-HIV antibody infusions suppress virus for prolonged period
  • 2022-08-05 9:0:00.0 ViiV Healthcare looks to make long-acting HIV prevention shot accessible in low- and middle-income countries
  • 2022-08-05 9:0:00.0 Injectable PrEP can only cost a little more than oral PrEP if it is to be cost-effective, South African study finds
  • 2022-08-05 9:0:00.0 ViiV agrees to expand access to long-acting HIV PrEP
  • 2022-08-05 9:0:00.0 Injectable HIV Prevention Better Than Pills in Two Trials
  • 2022-08-05 9:0:00.0 WHO recommends long-acting cabotegravir for HIV prevention
  • 2022-08-05 9:0:00.0 Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neu
  • 2022-08-05 9:0:00.0 Leading figures urge drugs firm to lower price of ‘game-changing’ HIV prevention drug
  • 2022-08-15 9:0:00.0 GlaxoSmithKline's long-acting HIV drug nabs FDA priority review as a preventative option
  • 2022-08-15 9:0:00.0 Injectable PrEP Works Equally Well for Transgender Women
  • 2022-09-16 9:0:00.0 Johnson & Johnson scores an FDA first with nod for twice-yearly schizophrenia drug Invega Hafyera
  • 2022-09-16 9:0:00.0 Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
  • 2022-09-16 9:0:00.0 Medicines Patent Pool and MedinCell sign license deal to fight malaria
  • 2022-10-10 10:0:00.0 FDA approves new HIV treatment for patients who have limited treatment options
  • 2022-10-07 9:0:00.0 Long-Acting Naltrexone Effective in Alcohol Use Disorder
  • 2022-10-21 9:0:00.0 Zimbabwe becomes first African nation to approve HIV prevention drug
  • 2022-11-04 9:0:00.0 EMA validates ViiV marketing authorisation application for Cabotegravir long-acting injectable for HIV prevention
  • 2022-11-11 9:0:00.0 South Africa expected to begin piloting HIV prevention shot in early 2023
  • 2022-11-11 9:0:00.0 MedinCell’s partner AIC registers trial for drug for total knee replacement pain
  • 2022-11-18 9:0:00.0 Nanexa AB has received approval initiate a clinical trial of its drug candidate NEX-2
  • 2022-11-25 9:0:00.0 Broadly Neutralizing Antibody Shows Promise for Long-Acting HIV Treatment
  • 2022-12-16 9:0:00.0 Astria Therapeutics Announces Positive Preliminary Results From The Phase 1a Clinical Trial Of STAR-0215 In Healthy Subjects
  • 2023-01-13 9:0:00.0 Astria Therapeutics Announces Positive Preliminary Results From The Phase 1a Clinical Trial Of STAR-0215 In Healthy Subjects
  • 2023-01-13 9:0:00.0 Using machine learning models to guide the design of long-acting injectable drug formulations
  • 2023-01-27 9:0:00.0 Study: Long-acting PrEP could reduce HIV incidence, AIDS deaths in sub-Saharan Africa
  • 2023-01-27 9:0:00.0 Twice-Yearly Sunlenca Works Well for Initial HIV Treatment
  • 2023-02-03 9:0:00.0 Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of T
  • 2023-02-10 9:0:00.0 New formulation can provide up to six months of full protection against HIV
  • 2023-02-17 9:0:00.0 Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
  • 2023-02-17 9:0:00.0 Reassuring Data on Durability of Long-Acting ART Every 8 Weeks
  • 2023-02-17 9:0:00.0 ViiV Healthcare to Present First Head-to-head Data for New HIV Treatment Regimen Cabenuva Against Biktarvy
  • 2023-02-17 9:0:00.0 Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)
  • 2023-02-24 9:0:00.0 GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill
  • 2023-02-24 9:0:00.0 PrEP implant could enable long-term HIV protection
  • 2023-03-03 9:0:00.0 Sanofi gets FDA nod for long-acting haemophilia A drug
  • 2023-03-03 9:0:00.0 Long-Acting Glatiramer Acetate Appears Safe and Effective in Large Trial
  • 2023-03-03 9:0:00.0 Long-Acting ART Suppresses HIV in Individuals Without Virological Suppression
  • 2023-03-03 9:0:00.0 Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option
  • 2023-03-24 9:0:00.0 Long-acting GIPRA inhibits feeding and lowers body weight in mice with diet-induced obesity
  • 2023-03-24 9:0:00.0 Top 5 stories on injectable HIV treatment and PrEP from CROI 2023
  • 2023-03-24 9:0:00.0 Doctor Gives Cutting-Edge HIV Treatment to SF’s Most Vulnerable
  • 2023-03-24 9:0:00.0 Doctor Gives Cutting-Edge HIV Treatment to SF’s Most Vulnerable
  • 2023-04-21 9:0:00.0 Skin patches may be more convenient MS antibody medicine
  • 2023-04-21 9:0:00.0 Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use
  • 2023-04-28 9:0:00.0 Valitor Presents Preclinical Data on its Long-acting Anti-VEGF Biologic in Development for Durable Treatment of Wet AMD at the Association for Research in Visio
  • 2023-04-28 9:0:00.0 FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI)
  • 2023-05-12 9:0:00.0 Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)
  • 2023-05-12 9:0:00.0 Anti-HIV injection to be made in South Africa
  • 2023-05-26 9:0:00.0 Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favourable characteristics
  • 2023-05-26 9:0:00.0 Phase 3 Study Finds Dupilumab Reduces COPD Exacerbations in Patients With Type 2 Inflammation
  • 2023-05-26 9:0:00.0 FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
  • 2024-01-29 9:0:00.0 Global Long-acting Therapeutics News from January 2024
  • 2024-02-09 9:0:00.0 Long-acting HIV Antiretrovirals adopted in Botswana
  • 2024-02-16 9:0:00.0 Medicenna Announce First Patient with Advanced Solid Tumours Dosed in ABILITY-1 Study of MDNA11 Combination with KEYTRUDA® (pembrolizumab)
  • 2024-02-16 9:0:00.0 Long-acting antiretroviral therapy (ART) maintains HIV virologic suppression regardless of obesity status
  • 2024-04-05 9:0:00.0 Innovative Long-acting Drug Delivery Platform Implanted in Eyes
  • 2024-04-12 9:0:00.0 Long-acting injectable for schizophrenia approved in the EU
  • 2024-04-12 9:0:00.0 Positive phase 2 study of zilebesiran for patients with hypertension
  • 2024-04-19 9:0:00.0 Long-acting oral combo for HIV maintains viral suppression at Week 24
  • 2024-04-19 9:0:00.0 Medincell enters into strategic co-development and licensing agreement with AbbVie to develop next-generation long-acting injectable therapies
  • 2024-04-26 9:0:00.0 Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS).
  • 2024-04-26 9:0:00.0 Unlocking innovative hydrogel treatments
  • 2024-05-10 13:46:01.0 New cabotegravir formulations approved to help prevent HIV-1 infection in adults and adolescents
  • 2024-05-17 10:46:00.0 SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population
  • 2024-05-17 10:46:00.0 Injectable HIV medication is superior to oral medication for patients who frequently miss doses
  • 2024-06-10 10:46:00.0 U.S. clinical trials begin for twice-yearly HIV prevention injection
  • 2024-06-10 10:46:00.0 New data provide schizophrenia treatment insights into switching to UZEDY® extended-release injectable suspension from invega sustenna®
  • 2024-06-14 10:46:00.0 Tirzepatide Shows Efficacy Resolving Metabolic Dysfunction-Associated Steatohepatitis without Worsening of Fibrosis
  • 2024-06-14 10:46:00.0 Namibian first ladies call for new HIV medicine
  • 2024-06-14 10:46:00.0 South Africa's roll-out of HIV prevention jabs stymied by price
  • 2024-06-28 10:46:00.0 Landmark Trial in South Africa and Uganda Finds Twice Yearly HIV Prevention Injection Safe and Highly Effective
  • 2024-07-05 10:46:00.0 ADAP Advocacy Publishes Final Report for Patient Perspectives on Long-Acting Injectables
  • 2024-07-05 10:46:00.0 Behavioural Providers Turn to Long-acting Injectables to Boost Adherence, Decrease Burden
  • 2024-07-05 10:46:00.0 New mRNA technology turns cells into long-lasting drug factories
  • 2024-07-22 10:46:00.0 Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
  • 2024-07-26 10:46:00.0 ViiV Healthcare announces positive new data for Apretude use during pregnancy at AIDS 2024
  • 2024-07-26 10:46:00.0 HIV drug could be made for just $40 a year for every patient
  • 2024-08-09 10:46:00.0 Concentric Analgesics Announces Data Highlighting Two Weeks of Durable Pain Relief and Earlier Cessation of Opioids in Two Surgical Procedures
  • 2024-08-16 10:46:00.0 Persist AI and Nivagen to Collaborate on AI-Driven Manufacturing Process for Long-Acting Injectable
  • 2024-08-23 10:46:00.0 Peptron to boost long-acting drug production 10-fold with new factory, investing ₩65 billion.
  • 2024-09-06 10:46:00.0 Nanoform and Celanese expand collaboration into long-acting biologics delivery through small implants
  • 2024-09-13 10:46:00.0 GSK present data at ERS for depemokimab an asthma medication that last 6 months.
  • 2024-09-13 10:46:00.0 First Patients Dosed in Debiopharm's Phase III Trial of a 12-Month Triptorelin Formulation for Children with Central Precocious Puberty
  • 2024-09-13 10:46:00.0 Innovative semaglutide hydrogel could reduce diabetes shots to once a month
  • 2024-09-20 10:46:00.0 Patent Applications for HIV Prevention Drug Opposed in India: Vulnerable Group Seeks to Protect Generic Competition to Lower Prices of HIV Prevention Drug Lena
  • 2024-10-04 10:46:00.0 Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
  • 2024-10-04 10:46:00.0 UNAIDS response to Gilead’s announcement on signing voluntary licensing agreements on lenacapavir with six generic manufacturers
  • 2024-11-01 10:46:00.0 EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degener
  • 2024-11-01 10:46:00.0 Long-Acting Degradable Implants for Endometriosis Treatment
  • 2024-11-01 10:46:00.0 First-ever long-acting injectable for malaria prevention administered to study volunteer
  • 2024-11-15 10:46:00.0 Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables